DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for compartment syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCompartment syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for compartment syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
synaptosome associated protein 25 (SNAP25) — SNAP25 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3RK2 · 2.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 2024 pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) analysed 2197 reports from the first quarter of 2004 to the third quarter of 2023 and found 100 drugs significantly associated with compartment syndrome. The median time from drug exposure to reported compartment syndrome was 45 days. The study calculated reporting odds ratios with 95% confidence intervals to detect positive signals, but it does not name which drugs were associated, nor does it provide any survival or response rate data. The authors state that further studies are needed to verify whether these drugs actually cause the risk.
Two identical 2024 review papers describe innovative approaches and alternatives to standard open fasciotomy for compartment syndrome. These papers aim to evaluate clinical applicability and discuss future research directions, but they provide no concrete numbers — no survival rates, no response rates, no sample sizes. They mention only the potential of new technologies to improve patient outcomes and reduce morbidity compared with traditional open fasciotomy.
No drug is named in any of these abstracts as a treatment for compartment syndrome. The pharmacovigilance study identifies drugs associated with the condition, not drugs that treat it. The review papers discuss technologies, not drugs. There is no evidence of any drug being repurposed for compartment syndrome in these abstracts.
What is still missing: prospective trials testing any specific drug as a treatment, patient stratification criteria, funding for comparative studies against standard fasciotomy, and any data on whether the drugs identified in the FAERS analysis are causal or merely coincidental.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Treatment of Compartment Syndrome: Innovative Breakthroughs and Alternatives to Standard Open Fasciotomy
AbstractThis paper aims to provide a thorough review of the current literature on these innovative approaches, evaluate their clinical applicability, and discuss the future directions of research and development in the treatment of compartment syndrome. Through this review, we seek to highlight the potential of these new technologies to improve patient outcomes and reduce the morbidity associated with traditional open fasciotomy.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Treatment of Compartment Syndrome: Innovative Breakthroughs and Alternatives to Standard Open Fasciotomy
AbstractThis paper aims to provide a thorough review of the current literature on these innovative approaches, evaluate their clinical applicability, and discuss the future directions of research and development in the treatment of compartment syndrome. Through this review, we seek to highlight the potential of these new technologies to improve patient outcomes and reduce the morbidity associated with traditional open fasciotomy.
Expert Opinion on Drug Safety · 2024 · 0 citations
Compartment syndrome associations with drugs: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)
AbstractBACKGROUND: Compartment syndrome is an uncommon but life-threatening condition. No study has comprehensively compared compartment syndrome (CS) association with available drugs. The objective of this study was to estimate the association between CS and drugs using the FDA Adverse Event Report System (FAERS). RESEARCH DESIGN AND METHODS: FAERS reports from the first quarter of 2004 to the third quarter of 2023 were analyzed. The Medical Dictionary for Regulatory Activities (MedDRA) was used to identify CS cases. Reporting odds ratio (ROR), corresponding to 95% confidence intervals (95% CI) were calculated to detect a positive signal. RESULTS: A total of 2197 reports were considered in the study after the inclusion criteria were applied. Totally 100 drugs were found to be associated with CS. The median time for drug-associated CS was 45 days. CONCLUSIONS: By analyzing the FAERS database, the study revealed that certain drugs are significantly associated with compartment syndrome. Further studies are needed to verify whether these drugs are associated with such a risk.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
